FDA approves new lung cancer diagnostic tool, intraveneous opioid

Aug 10, 2020 - 03:00 PM
FDA product update

The Food and Drug Administration Friday approved the first liquid biopsy companion diagnostic that uses next-generation sequencing technology to identify patients with specific gene mutations in a deadly form of metastatic non-small cell lung cancer.

“In addition to benefitting from less invasive testing, patients are provided with a simultaneous mapping of multiple biomarkers of genomic alterations, rather than one biomarker at a time, which can translate to decreased wait times for starting treatment and provide insight into possible resistance mechanisms,” said Tim Stenzel, M.D., director of FDA’s Office of In Vitro Diagnostics and Radiological Health.

In other news, the agency Friday approved a new intraveneous opioid for managing acute pain in adults in hospital and other controlled clinical settings, such as inpatient and outpatient procedures. The drug, Olinvyk (oliceridine), has a maximum recommended daily dose limit of 27 milligrams.

Related News Articles

Headline
FDA issues serious recall for electric wheelchair joysticks
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
FDA recalls certain coaxial breathing sets, resuscitators, other products
The Food and Drug Administration has identified Class I recalls for the following products due to the potential for serious injury or death:Certain lots of…
Headline
AHA podcast: HCA’s AI-Driven Patient Safety Evolution, Part 1
Randy Fagin, M.D., chief quality officer at HCA Healthcare, shares insights into the organization’s bold approach to improving safety outcomes. From piloting…
Headline
AHA blog highlights Quest for Quality Prize, health systems leading in quality and safety
The AHA Quest for Quality Prize honors hospitals and health systems committed to leadership and innovation in improving quality and advancing health. Learn how…
Headline
Weather threats to drug production facilities examined in study
A JAMA study published Aug. 20 found that nearly 63% of all U.S. drug production facilities from 2019 through 2024 were in counties where a weather disaster…
Blog
Reimagining health care: How two systems are leading the charge in quality and safety
Read about the 2025 Quest for Quality Prize winner and finalist — and apply for the 2026 awardEach day, health care professionals across the U.S. leverage…